BRPI0707700B8 - composição farmacêutica compreendendo um derivado de 1,2,4-tiadiazol e derivado de 1,2,4-tiadiazol - Google Patents

composição farmacêutica compreendendo um derivado de 1,2,4-tiadiazol e derivado de 1,2,4-tiadiazol

Info

Publication number
BRPI0707700B8
BRPI0707700B8 BRPI0707700A BRPI0707700A BRPI0707700B8 BR PI0707700 B8 BRPI0707700 B8 BR PI0707700B8 BR PI0707700 A BRPI0707700 A BR PI0707700A BR PI0707700 A BRPI0707700 A BR PI0707700A BR PI0707700 B8 BRPI0707700 B8 BR PI0707700B8
Authority
BR
Brazil
Prior art keywords
thiadiazole derivative
disease
pharmaceutical composition
thiadiazole
derivative
Prior art date
Application number
BRPI0707700A
Other languages
English (en)
Inventor
Griffioen Gerard
Marie Edith Coupet Kristel
Roger Duhamel Hein
Wera Stefaan
Gomme Ellen
Van Damme Nele
Van Der Auwera Ingrid
Lox Marleen
Van Dooren Tom
Decruy Tine
Original Assignee
Nv Remynd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nv Remynd filed Critical Nv Remynd
Publication of BRPI0707700A2 publication Critical patent/BRPI0707700A2/pt
Publication of BRPI0707700B1 publication Critical patent/BRPI0707700B1/pt
Publication of BRPI0707700B8 publication Critical patent/BRPI0707700B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE TIADIAZOL PARA TRATAMENTO DE DOENÇAS NEURODEGENERATIVAS. A presente invenção refere-se a derivados de 1,2,4-tiadiazol especificamente substituído para uso no tratamento de uma a-sinucleopatia, tal como mal de Parkinson, doença difusa dos corpúsculos de Lewy, lesão cerebral traumática, esclerose amiotrófica lateral, doença de Niemann-Pick, síndrome Hallervorden-Spatz, síndrome de Down, distrofia neuroaxonal, atrofia de sistemas múltiplos e mal de Alzheimer.
BRPI0707700A 2006-02-07 2007-02-07 composição farmacêutica compreendendo um derivado de 1,2,4-tiadiazol e derivado de 1,2,4-tiadiazol BRPI0707700B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0602335.2 2006-02-07
GBGB0602335.2A GB0602335D0 (en) 2006-02-07 2006-02-07 Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases
PCT/EP2007/001022 WO2007090617A2 (en) 2006-02-07 2007-02-07 Thiadiazole derivatives for the treatment of neuro degenerative diseases

Publications (3)

Publication Number Publication Date
BRPI0707700A2 BRPI0707700A2 (pt) 2011-05-10
BRPI0707700B1 BRPI0707700B1 (pt) 2020-08-04
BRPI0707700B8 true BRPI0707700B8 (pt) 2022-12-20

Family

ID=36101115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707700A BRPI0707700B8 (pt) 2006-02-07 2007-02-07 composição farmacêutica compreendendo um derivado de 1,2,4-tiadiazol e derivado de 1,2,4-tiadiazol

Country Status (15)

Country Link
EP (1) EP1981504B1 (pt)
JP (1) JP5283511B2 (pt)
CN (1) CN101378757B (pt)
AT (1) ATE474579T1 (pt)
AU (1) AU2007213954B2 (pt)
BR (1) BRPI0707700B8 (pt)
CA (1) CA2641453C (pt)
DE (1) DE602007007890D1 (pt)
DK (1) DK1981504T3 (pt)
EA (1) EA018067B1 (pt)
ES (1) ES2348999T3 (pt)
GB (1) GB0602335D0 (pt)
PL (1) PL1981504T3 (pt)
PT (1) PT1981504E (pt)
WO (1) WO2007090617A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536168B2 (en) * 2007-03-15 2013-09-17 Novartis Ag Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
US20090325964A1 (en) * 2008-05-23 2009-12-31 Wyeth Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression
JP5713352B2 (ja) * 2008-06-27 2015-05-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チアジアゾリルオキシフェニルアミジン類及び殺菌剤としてのそれらの使用
US8906330B2 (en) 2009-05-04 2014-12-09 Basf Corporation Lean HC conversion of TWC for lean burn gasoline engines
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2013004642A1 (en) 2011-07-01 2013-01-10 Remynd Nv 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases
JP6051218B2 (ja) * 2011-08-17 2016-12-27 リマインド・ナムローゼ・フエンノートシャップＲｅｍｙｎｄ Ｎｖ アルツハイマー病等のタウオパチーの治療に有用なピペラジンチアジアゾール誘導体
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN115368356B (zh) 2013-12-20 2025-05-09 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
US10562869B2 (en) 2014-03-17 2020-02-18 Remynd Nv Oxadiazole compounds
AU2021324684A1 (en) * 2020-08-11 2023-04-20 Board Of Trustees Of Michigan State University Proteasome enhancers and uses thereof
CN122206438A (zh) 2023-11-13 2026-06-12 瑞敏德股份有限公司 用于在预防和/或治疗神经退行性障碍中使用的隔膜蛋白6的调节剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060472A (en) 1998-04-06 2000-05-09 Apotex Inc. Thiadiazole compounds useful as inhibitors of H+ /K+ atpase
US6699866B2 (en) * 2001-04-17 2004-03-02 Sepracor Inc. Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
BRPI0413709A (pt) * 2003-08-21 2006-10-17 Pfizer Prod Inc compostos para o tratamento de distúrbios neurodegenerativos
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
DE102004032567A1 (de) * 2004-07-05 2006-03-02 Grünenthal GmbH Substituierte 1-Propiolyl-piperazine

Also Published As

Publication number Publication date
JP2009526000A (ja) 2009-07-16
GB0602335D0 (en) 2006-03-15
EA200870233A1 (ru) 2009-02-27
PT1981504E (pt) 2010-10-13
AU2007213954B2 (en) 2011-09-22
AU2007213954A1 (en) 2007-08-16
DK1981504T3 (da) 2010-11-08
EA018067B1 (ru) 2013-05-30
HK1122989A1 (en) 2009-06-05
EP1981504B1 (en) 2010-07-21
CA2641453A1 (en) 2007-08-16
BRPI0707700B1 (pt) 2020-08-04
ES2348999T3 (es) 2010-12-21
CA2641453C (en) 2013-07-30
PL1981504T3 (pl) 2010-12-31
JP5283511B2 (ja) 2013-09-04
WO2007090617A2 (en) 2007-08-16
CN101378757B (zh) 2012-08-01
ATE474579T1 (de) 2010-08-15
DE602007007890D1 (de) 2010-09-02
WO2007090617A3 (en) 2008-02-28
EP1981504A2 (en) 2008-10-22
CN101378757A (zh) 2009-03-04
BRPI0707700A2 (pt) 2011-05-10

Similar Documents

Publication Publication Date Title
EA200870233A1 (ru) Производные тиадиазола для лечения нейродегенеративных заболеваний
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
EP1986639A4 (en) PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
MX2010013020A (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
CL2011001098A1 (es) Compuestos derivados de 4-fluoro-1h-isoindol-3-amina; inhibidores de b-secretasa (bace); composicion farmaceutica; y su uso para el tratamiento o prevencion de una patologia relacionada con la proteina beta amiloide tal como sindrome de down, alzheimer, demencia senil y demencia asociada con parkinson, entre otras.
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
BRPI1008727A2 (pt) derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos
WO2009154304A3 (en) A pharmaceutical composition comprising rebamipide
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
CL2008000738A1 (es) Compuestos derivados de malonamida; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la depresion, enfermedad de parkinson y alzheimer, entre otras enfermeda
IL189270A (en) Repamycins converted to phosphonate and their derivatives, pharmaceutical preparations containing them and their use in the prevention and treatment of bone and joint infections
WO2009019295A3 (en) Phenyl- and benzylthiazolylpiperazine derivatives for the treatment of neurodegenerative diseases
ZA200709094B (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility
IL186831A0 (en) 4-phenyl- 5-oxo - 1,4,5,6,7,8 - hexahydroquinoline derivatives as medicaments for the treatment of infertility
ATE458748T1 (de) Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel
TNSN08537A1 (fr) Precurseurs de medicaments du type peneme
IL188848A (en) A transient receptor antagonist (TRPVI) i, a pharmaceutical preparation containing it for the treatment of related diseases and conditions.
BR112012015170A8 (pt) Derivado de amino-heteroarila, composição farmacêutica, uso de um derivado de amino-heteroarila, e, método para tratamento de dor
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
IL202221A (en) Transdermal Preparation of 1- (Benzoforan-2-Il) -2-Propylaminopentane for the Treatment of Alzheimer's, Parkinson's, Depression, Psychosis and Drug Dependence
ATE450273T1 (de) Proliferationshemmendes arzneimittel
WO2008014232A3 (en) Pharmaceutical formulations for the treatment of alzheimer's disease
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
WO2008112701A3 (en) G-substrate for the treatment and prevention of parkinson's disease

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2587 DE 04/08/2020 QUANTO AO ENDERECO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2760 DE 28-11-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.